Weill Cornell Maps Sevoflurane Binding to Sodium Channels

Researchers at Weill Cornell Medicine and Birkbeck, University of London, have identified the precise binding site at which a widely used inhaled anaesthetic attaches to sodium ion channels, resolving a mechanistic question that has puzzled anaesthesiology for 175 years. Published in Nature Communications on 19 June 2026, the study provides the first atomic-level view of how sevoflurane binds to sodium channels and stabilises them in an inactive state.

Sodium channels regulate the flow of charged particles across cell membranes, enabling neurons to generate the electrical signals that underpin brain communication. Inhaled anaesthetics have long been suspected to interact with these channels, but mammalian sodium channels are too large and structurally complex for the detailed analysis needed to visualise weak anaesthetic binding. The team turned to voltage-gated sodium channels from the marine bacterium Magnetococcus marinus, which are structurally simpler but share the same sensitivity to anaesthetics, and used high-resolution X-ray crystallography to capture snapshots of sevoflurane bound to the channel.

Sevoflurane tucks into a small pocket at the edge of the channel’s pore-forming region, away from the pathway through which sodium ions flow. Binding at this location stabilises the channel in an inactive state, reducing the neuron’s ability to transmit electrical signals. Altering a single amino acid in the binding pocket eliminated sevoflurane’s effect entirely. Dr Hugh Hemmings, chair of Anaesthesiology at Weill Cornell, framed the work as opening a route toward safer, more selective anaesthetics with fewer side effects, with the team now translating findings into mammalian systems.

The commercial signal is a concrete structural target for next-generation anaesthetic drug design, in a category where safety profile and inter-patient response variability remain unresolved commercial and clinical challenges. Expect renewed interest from pharma developers exploring newer inhaled anaesthetics, and from precision medicine platforms working to identify genetic markers predicting anaesthesia response. It has taken 175 years to reach this level of mechanistic clarity.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Bailey Osborne today!